Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on May 20, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

NOI to Sole Source to One Lambda, Inc.

Awarded
NOI-OD-26-000027Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 339112
New
Federal
Shoulder Innovation System
Solicitation # HT941027N0008
The Defense Health Agency Contracting Activity intends to award a firm-fixed-price, sole-source purchase order to Source Medical Systems, INC for a Shoulder Innovation System. This procurement is designated as an 8(a) sole source under NAICS code 339112 to support an emergency procedure at Madigan Army Medical Center in Tacoma, Washington. The system is required for a patient with a proximal humerus fracture and a very small glenoid with moderate superior inclination, necessitating a reverse shoulder arthroplasty. The specific system is required because it provides a lower profile glenoid baseplate and a specialized mechanism for surgical planning and deformity correction, which are proprietary components distributed exclusively by the original equipment manufacturer. The delivery date for the system is set for October 27, 2026. While the government intends to proceed with a sole-source award due to the proprietary nature of the equipment, it has issued a notice of intent allowing other interested vendors to challenge the sole-source basis. To do so, vendors must submit a capability statement including management, technical, and cost data no later than 10:00 AM Pacific Daylight Time on October 28, 2026. These statements must be submitted in Microsoft Word or PDF format, not exceed six pages, and be sent to the primary points of contact, Joshua Thompson and Tracy Robinson.
Department Of Defense

POSTED

about 16 hours ago

DEADLINE

in about 13 hours
NAICS: 339112
New
Federal
6640--Perfusion Cell Saver Lease and Service
Solicitation # 36C26127Q0077
The Department of Veterans Affairs Network Contracting Office 21 is soliciting quotes for a firm-fixed price contract to provide Intra-Operative Non-Cardiac Autotransfusion professional services and a leased cell saver machine, such as the LivaNova Xtra ATS System or equal, for the VA Sierra Nevada Healthcare System in Reno, Nevada. The scope of work includes providing a credentialed auto-transfusionist to suction, wash, and centrifuge red blood cells for re-infusion during surgical cases, with an estimated annual volume of 12 procedures. The contract is structured with a base period from November 1, 2026, to October 31, 2027, and four subsequent one-year option periods extending through October 31, 2031. This procurement is designated as a HUBZONE Small business set-aside, though evaluation factors provide specific credit for Service-Disabled Veteran-Owned Small Businesses and Veteran-Owned Small Businesses. Award will be based on the most advantageous offer considering technical capabilities, delivery timelines, price reasonableness, and authorization from the Original Equipment Manufacturer or an authorized distributor. Key requirements include compliance with Class I, Type B electrical safety standards, strict labeling of autologous units, and the provision of identity theft insurance. Following several amendments to clarify technical specifications and correct clerical errors, the final response deadline is October 29, 2026, at 12:00 EDT.
261-NETWORK Contract Office 21 (36C261)

POSTED

about 16 hours ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The National Institutes of Health intends to award a one-year, firm-fixed-price sole source contract to One Lambda Inc. for the supply of HLA typing and antibody screening reagents essential for transplant protocols at the NIH Clinical Center in Bethesda, Maryland. The reagents—including LABType, LABScreen, and Secore kits—are exclusively manufactured by One Lambda, and no alternative vendors can provide equivalent products without extensive and time-consuming validation, which would disrupt patient testing for approximately two months. The lab has already validated these reagents for accuracy and precision, confirming their superior ability to resolve testing ambiguities. The contract will be executed under FAR Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), which permits sole source procurement when only one source is reasonably available, thereby exempting the acquisition from full competition requirements. Deliveries will be made on an as-needed or requested basis, with reagents required to be shipped within one week of order placement, unless otherwise specified. The performance period is estimated from June 2026 through May 2027, and the place of performance is the NIH Clinical Center, Bethesda, MD 20892. The procurement falls under NAICS Code 339112 for Surgical and Medical Instrument Manufacturing and the Product Service Code 6640 for Laboratory Equipment and Supplies. Comments on the intent to award without competition must be submitted by May 27, 2026, to the designated point of contact, Huda Malik, via email. The contract does not include competitively derived pricing, nor are formal inspection, packaging, or payment terms specified, as the award is based solely on the uniqueness of the product and established vendor reliability.

General Info

NIH awards One Lambda one-year sole source contract for HLA reagents, ensuring timely transplant support.

NAICS

339112 - Surgical and Medical Instrument Manufacturing

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

1

Justification for Other than Full and Open Competition for One Lambda Reagents FY26

DOCX, High priority: read this firstjustification-and-authorization
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseAwarded
Posted

Presolicitation

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
Contacts1 person available
OfficeBETHESDA, MD, 20892, USA
Office AddressBETHESDA, MD, 20892, USA
Contacts

Full Description

Show more

The purpose of this acquisition is to provide HLA typing and antibody screening reagents to the HLA Lab on a regular basis.  One Lambda (vendor) will ship reagents included on the quote on an “as needed/requested” basis. Vendor will provide the reagents within 1 week, unless otherwise specified during ordering.


•             Product Service Code: 6640 – Laboratory Equipment and Supplies


•             NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing


•             Place of Performance: NIH Clinical Center, Bethesda, MD 20892 USA


POTS: 26-000027


Description:


This is a notice of intent, not a request for a quotation.  A solicitation document will not be issued, and quotations will not be requested.


The National Institutes of Health (NIH) intends to award a one-year contract to One Lambda Inc., located at 22801 Roscoe Blvd, West Hills, CA 91304, on a firm fixed price sole source award basis for the purchase of Reagents for HLA Typing and Antibody Screening of NIH Transplant Protocols.


The proposed vendor, One Lambda Inc., is the only manufacturer of these specific HLA typing and antibody screening reagents. The HLA Lab currently uses these reagents to test our patients.  The reagents provided by One Lambda have been previously tested in the lab and provide a greater ability to resolve testing ambiguities than other vendors tested.  All validation testing has been completed for these reagents so there is laboratory documentation available to confirm the accuracy and precision of these reagents.  A change in vendors/reagents would require extensive validation and would take approximately 2 months.  This would greatly impact the ability of the HLA Lab to provide timely results.


This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.  Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.


The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.


Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Huda Malik, Contract Specialist via email to contact@example.gov by May 27, 2026 by 10 am EST.

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

NAICS: 541690
New
Federal
Clinical Research Support and Collaboration for NHGRI Protocols
Solicitation # 75N98026R00034
The National Institutes of Health Office of Acquisitions and Logistics Management, on behalf of the National Human Genome Research Institute, is soliciting proposals for an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to provide comprehensive clinical research support and collaboration services. This small business set-aside acquisition focuses on four primary task areas: protocol monitoring and data management, regulatory support for IND and IDE submissions, Data Safety and Monitoring Board (DSMB) support, and statistical expertise. The contractor must provide qualified personnel experienced in clinical trial design and regulatory requirements, with specific expertise in rare diseases, genetic conditions, gene therapy using AAV9 vectors, and both pediatric and adult populations. The contract features a three-year ordering period beginning January 1, 2027, with performance primarily occurring at the contractor's site and some travel to the NIH campus in Bethesda, Maryland. Award will be made on a competitive best value basis using a tradeoff approach, where non-price factors—including personnel, technical and management approach, offeror experience, and past performance—are significantly more important than cost. Task orders will be issued as either firm fixed-price or time and materials. The contract includes stringent requirements for cybersecurity, the handling of Controlled Unclassified Information, and compliance with Section 508 accessibility standards for all electronic deliverables. Proposals are due by November 13, 2026, and must be submitted via the NIH electronic Contract Proposal Submission website in separate technical and business volumes.
Other Scientific and Technical Consulting Services

POSTED

1 day ago

DEADLINE

in 17 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS